{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:34:36Z","timestamp":1793612076546,"version":"4.5.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000002","name":"NIH\/NCI","doi-asserted-by":"publisher","award":["R01-CA207295"],"award-info":[{"award-number":["R01-CA207295"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH\/NCI","doi-asserted-by":"publisher","award":["U01-CA213273"],"award-info":[{"award-number":["U01-CA213273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH\/NCI","doi-asserted-by":"publisher","award":["P5-CA070907"],"award-info":[{"award-number":["P5-CA070907"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH\/NCI","doi-asserted-by":"publisher","award":["NIH\/NCIP30-CA01667"],"award-info":[{"award-number":["NIH\/NCIP30-CA01667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>Mutations in STK11 (LKB1) are a major cause of primary resistance to immunotherapy in non\u2013small cell lung cancer. Kitajima and colleagues dissect the underlying mechanism of this immune-resistant phenotype, demonstrating that LKB1 loss leads directly to suppression of stimulator of interferon genes (STING) and insensitivity to cytoplasmic double-strand DNA detection. Therapies that reactivate LKB1 or theSTING pathway may boost anticancer immune response in cancers with resistance to immune-checkpoint blockade.<\/jats:p>\n                    <jats:p>See related article by Kitajima et al., p. 34.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-18-1286","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T08:35:14Z","timestamp":1547022914000},"page":"16-18","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers"],"prefix":"10.1158","volume":"9","author":[{"given":"Carminia Maria","family":"Della Corte","sequence":"first","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Averett","family":"Byers","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"2022060701314536300_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"2022060701314536300_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc2676","article-title":"The LKB1-AMPK pathway: metabolism and growth control in tumor suppression","volume":"9","author":"Shackelford","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022060701314536300_bib3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"2022060701314536300_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"2022060701314536300_bib5","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2018.36.15_suppl.3028","article-title":"Somatic STK11\/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC","volume":"36","author":"Kunkel","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022060701314536300_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"2022060701314536300_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/tlcr.2018.02.03","article-title":"Targeting DNA damage repair in small cell lung cancer and the biomarker landscape","volume":"7","author":"Sen","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2022060701314536300_bib8","doi-asserted-by":"crossref","first-page":"LBA15","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann Oncol"},{"key":"2022060701314536300_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"2022060701314536300_bib10","first-page":"115","article-title":"MV-626, a potent and selective inhibitor of ENPP1 enhances STING activation and augments T-cell mediated anti-tumor activity in vivo","volume":"6","author":"Baird","year":"2018","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/1\/16\/1847190\/16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/1\/16\/1847190\/16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T21:35:00Z","timestamp":1654551300000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/1\/16\/10504\/Evading-the-STING-LKB1-Loss-Leads-to-STING"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,9]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-18-1286","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}